Related Experiment Video
Updated: May 5, 2026

Control of Eating Behavior Using a Novel Feedback System
Published on: May 8, 2018
Vykat XR (diazoxide choline-extended release): a new FDA-approved treatment for hyperphagia in Prader-Willi syndrome
Prakriti Pokhrel1,2, Hidhaya S Noorul3, Laraib Fatima4
1Department of Psychiatry, Kathmandu Medical College and Teaching Hospital, Kathmandu, Nepal.
Abstract:
On March 27, 2025, the U.S. Food and Drug Administration (FDA) approved Vykat XR (diazoxide choline-extended release tablets) for the treatment of hyperphagia in individuals aged 4 years and older with Prader-Willi Syndrome (PWS). This marks the first FDA-approved pharmacologic therapy targeting hyperphagia in this population, addressing a long-standing unmet need and offering new hope for patients, caregivers, and clinicians.
Related Concept Videos
Oral Drug Delivery Systems: Continuous-Release Systems
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Drug Dosing: Obese Patients
FDA Approved Drugs: Changes to Approved Drugs

